Skip to content

Chinook Therapeutics, Inc.

CIK 0001435049

← back to feed
Revenue (TTM)
$5.76M
−88.1% YoY Q2 Aug 2023
Net Income (TTM)
−$220.75M
−82.5% YoY Q2 Aug 2023
EPS Diluted (TTM)
−$3.23
−29.2% YoY Q2 Aug 2023
Gross Margin
—
Q2 Aug 2023
Operating Margin
-3,968.8%
Q2 Aug 2023
Net Margin
-3,835.8%
Q2 Aug 2023
Free Cash Flow (TTM)
−$108.88M
Q2 Aug 2023
Cash
$127.15M
Q2 Aug 2023
Total Debt
—
Q2 Aug 2023
Shares Outstanding
71.8M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings